Resynchronisation pacing shows promise in final MUSTIC data
This article was originally published in Clinica
A multicentre European team claims that data is now available to validate biventricular pacing as a new resynchronisation therapy for patients with severe congestive heart failure (CHF) and major intraventricular conduction delay. However, the findings also appear to suggest that the number of patients who could benefit from the treatment might not be as large as previously thought.
You may also be interested in...
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
Results of a forthcoming APhA survey showed about one-third cannot store Pfizer/BioNTech's BNT162b2, but can handle Moderna's mRNA-1273.